BT Group H1 Pre-tax Income Falls, But Revenue Rises

BT Group Plc (BT), a British telecommunications firm, on Thursday posted a decline in pre-tax earnings for the first-half, that reflected increased depreciation from network build and higher specific costs.

However, the company's revenue moved up due to growth in Consumer and Openreach divisions.

For the first-half to September 30, the UK-based company posted a pre-tax income of 831 million pounds, compared with 1.009 billion pounds a year ago.

Post-tax earnings were at 893 million pounds or 9.1 pence per basic share, higher than last year's 431 million pounds or 4.4 pence per share, posted for the same period of 2021.

Excluding items, basic earnings per share fell to 10 pence from 10.2 pence per share, posted for the first-half of 2021.

Adjusted EBITDA stood at 3.873 billion pounds as against 3.748 billion pounds a year ago.

Consumer division generated adjusted revenues of 4.992 billion pounds, versus 4.857 billion pounds of previous year.

Adjusted revenue from Openreach division was at 2.836 billion pounds, higher than 2.707 billion pounds, posted for the first-half of 2021.

The Group reported total revenue of 10.366 billion pounds, higher than 10.305 billion pounds, a year ago.

BT Group has declared an interim dividend of 2.31 pence per share, unchanged from last year's 2.31 pence per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
Follow RTT